FDA rejects UCB's psoriasis therapy bimekizumab

The FDA has delivered a blow to UCB's late-stage pipeline, after saying it is unable to approve its latecomer IL-17 inhibitor bimekizumab for moderate-to-severe plaque psoriasis.

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including

UCB's bimekizumab 'pre-approved' using NICE fast-track schem...

UCB's bimekizumab hasn't been approved for marketing in Europe yet, but has already been given the nod for NHS use in England and Wales under a new fast-track scheme introduced by NICE.

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasi...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to th

UCB posts more supportive data from Humira rival bimekizumab

There’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and UCB’s contender bimekizumab is shaping up for a challenge with another

UCB’s bimekizumab tops J&J’s Stelara in psoriasis study